{"protocolSection": {"identificationModule": {"nctId": "NCT00899470", "orgStudyIdInfo": {"id": "CV181-081"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)", "officialTitle": "Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 500 mg Metformin IR Tablet Co-administered to Healthy Subjects in a Fasted and in a Fed State"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-05-08", "studyFirstSubmitQcDate": "2009-05-11", "studyFirstPostDateStruct": {"date": "2009-05-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-21", "resultsFirstSubmitQcDate": "2011-02-28", "resultsFirstPostDateStruct": {"date": "2011-03-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-08", "lastUpdatePostDateStruct": {"date": "2015-06-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to healthy subjects in a fasted and in a fed state."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)", "type": "EXPERIMENTAL", "description": "Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M \\[fasted\\]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M \\[fed\\]) followed by S/M under fasting conditions (S/M \\[fasted\\]) followed by S + M under fed conditions (S + M \\[fed\\])", "interventionNames": ["Drug: Co-administration of Saxagliptin and Metformin IR, Fasted", "Drug: Saxagliptin/Metformin, Fasting", "Drug: Co-administration of Saxagliptin and Metformin IR, Fed", "Drug: Saxagliptin/Metformin, Fed"]}, {"label": "S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)", "type": "EXPERIMENTAL", "description": "Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)", "interventionNames": ["Drug: Co-administration of Saxagliptin and Metformin IR, Fasted", "Drug: Saxagliptin/Metformin, Fasting", "Drug: Co-administration of Saxagliptin and Metformin IR, Fed", "Drug: Saxagliptin/Metformin, Fed"]}, {"label": "S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)", "type": "EXPERIMENTAL", "description": "Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)", "interventionNames": ["Drug: Co-administration of Saxagliptin and Metformin IR, Fasted", "Drug: Saxagliptin/Metformin, Fasting", "Drug: Co-administration of Saxagliptin and Metformin IR, Fed", "Drug: Saxagliptin/Metformin, Fed"]}, {"label": "S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)", "type": "EXPERIMENTAL", "description": "Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)", "interventionNames": ["Drug: Co-administration of Saxagliptin and Metformin IR, Fasted", "Drug: Saxagliptin/Metformin, Fasting", "Drug: Co-administration of Saxagliptin and Metformin IR, Fed", "Drug: Saxagliptin/Metformin, Fed"]}], "interventions": [{"type": "DRUG", "name": "Co-administration of Saxagliptin and Metformin IR, Fasted", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions", "armGroupLabels": ["S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)", "S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)", "S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)", "S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Saxagliptin/Metformin, Fasting", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions", "armGroupLabels": ["S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)", "S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)", "S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)", "S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)"], "otherNames": ["Onglyza", "Glucophage"]}, {"type": "DRUG", "name": "Co-administration of Saxagliptin and Metformin IR, Fed", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions", "armGroupLabels": ["S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)", "S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)", "S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)", "S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)"]}, {"type": "DRUG", "name": "Saxagliptin/Metformin, Fed", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions", "armGroupLabels": ["S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)", "S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)", "S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)", "S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Saxagliptin Mean Maximum Observed Plasma Concentration (Cmax)", "description": "Cmax of single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Saxagliptin Mean Area Under the Plasma Concentration Time Curve From Time Zero To Time of Last Quantifiable Concentration (AUC [0-T]}", "description": "AUC (0-T) for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Saxagliptin Mean Area Under the Plasma Concentration Time Curve From Time Zero To Infinity (AUC [0-INF])", "description": "AUC (0-T) for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Saxagliptin Mean Plasma Half-life (T-half) and Mean Time of Maximum Observed Plasma Concentration (T-max)", "description": "T-half and T-max for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg) or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Metformin Mean Cmax", "description": "Cmax of single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Metformin Mean AUC (0-T)", "description": "AUC (0-T for single-dose metformin (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Metformin Mean AUC(0-INF)", "description": "AUC (0-INF) for single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Metformin T-half and T-max", "description": "T-half and T-max for single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg), or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}], "secondaryOutcomes": [{"measure": "BMS-510849 Mean Cmax", "description": "Cmax of the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administered as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "BMS-510849 Mean AUC (0-T)", "description": "AUC (0-T) for the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administration as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "BMS-510849 Mean AUC (0-INF)", "description": "AUC (0-T)= for the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administered as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "BMS-510849 Mean T-half and T-max", "description": "T-half and Tmax of the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administerd as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr"}, {"measure": "Number of Participants With at Least 1 Adverse Event (AE), Death, Serious AE (SAE), or AEs Leading to Discontinuation", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.", "timeFrame": "From Day 1 through Day 45, including up to 56 days after last dose of study medication"}, {"measure": "Number of Participants With Laboratory Marked Abnormalities", "description": "High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Leukocytes: \\<0.9 x LLN/ \\>1.2 x ULN; blood urea nitrogen (BUN): \\>1.1 x ULN; creatinine: \\>1.33 x BL; phosphorous (P): \\<0.75 x LLN/ \\>1.2 5 x ULN; creatinine kinase (CK): \\>1.5 x ULN; urine blood=use \u22652 x BL if value \u22652+ or BL1+", "timeFrame": "From Day 1 through Day 45, including up to 56 days after last dose of study medication"}, {"measure": "Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities", "description": "PR interval, QRS complex, width of QRS, QT interval, and QT corrected for heart rate adjusting for heart rate using either Bazett formula or Fridericia formula were measured. ECG abnormalities were judged to be of medical importance by the Investigator.", "timeFrame": "Period 1 Day 1, Period 2 Day 1, Period 3 Day 1, Period 4 Day 1, Period 4 Day 3"}, {"measure": "Number of Participants With Clinically Relevant Vital Sign Abnormalities", "description": "Mean systolic and diastolic blood pressure, heart rate, respiration, and temperature were assessed.Vital sign abnormalities abnormalities were judged to be of medical importance by the Investigator.", "timeFrame": "Period 1 Day 1, Period 2 Day 1, Period 3 Day 1, Period 4 Day 1, Period 4 Day 3"}, {"measure": "Number of Participant With Clinically Relevant Physical Examination Abnormalities", "description": "A physical examination was conducted which included height and weight measurements, from which the Body Mass Index was determined. Physical examination abnormalities were judged to be of medical importance by the Investigator.", "timeFrame": "Screen, Period 1 Day -1, prior to discharge"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women ages 19 to 45 inclusive\n* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations\n* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \\[height (m)\\]2\n\nExclusion Criteria:\n\n* Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product\n* Any significant acute or chronic medical illness\n* Current or recent (within 3 months) gastrointestinal disease\n* Any major surgery within 4 weeks of study drug administration\n* History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds\n* History of allergy or intolerance to metformin or other similar acting agents\n* Prior exposure to saxagliptin\n* Prior exposure to metformin within 3 months of study drug administration.\n* Estimated creatinine clearance (Clcr) of \\< 80ml/min using the Cockcroft Gault formula", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "19 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Mds Pharma Services", "city": "Lincoln", "state": "Nebraska", "zip": "68502", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}]}, "referencesModule": {"references": [{"pmid": "23549864", "type": "DERIVED", "citation": "Upreti VV, Keung CF, Boulton DW, Chang M, Li L, Tang A, Hsiang BC, Quamina-Edghill D, Frevert EU, Lacreta FP. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects. Clin Drug Investig. 2013 May;33(5):365-74. doi: 10.1007/s40261-013-0075-z."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "85 participants were enrolled and 24 were treated on study. 61 participants discontinued before randomization and treatment due to: no longer meeting study criteria (n=36), withdraw of consent (n=3), study was full (n=15), participant did not call for results (n=1), completed alternate status (n=5), or did not show for check-up (n=1)", "groups": [{"id": "FG000", "title": "S+M (Fasted)> S/M (Fed)> S/M (Fasted)>S+M (Fed)", "description": "Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M \\[fasted\\]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M \\[fed\\]) followed by S/M under fasting conditions (S/M \\[fasted\\]) followed by S + M under fed conditions (S + M \\[fed\\])"}, {"id": "FG001", "title": "S/M (Fasted)> S+M (Fasted)> S+M (Fed)> S/M (Fed)", "description": "Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)"}, {"id": "FG002", "title": "S+M (Fed)> S/M (Fasted) >S/M (Fed)> S+M (Fasted)", "description": "Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)"}, {"id": "FG003", "title": "S/M (Fed)> S+M (Fed)> S+M (Fasted)> S/M (Fasted)", "description": "Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)"}], "periods": [{"title": "First Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "First Washout Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Second Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Second Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Third Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Third Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Fourth Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Treated Participants", "description": "Participants were randomized to received 1 of 4 treatments 1)oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions, 2) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions, 3) oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions, or 4) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions. Participants received all 4 treatments in 1 of 4 sequences: 1-4-2-3, 2-1-3-4, 3-2-4-1, or 4-3-1-2, with a washout period between treatments of at least 1 week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28", "spread": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Saxagliptin Mean Maximum Observed Plasma Concentration (Cmax)", "description": "Cmax of single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.57", "spread": "2.572"}, {"groupId": "OG001", "value": "8.61", "spread": "2.266"}, {"groupId": "OG002", "value": "11.36", "spread": "2.875"}, {"groupId": "OG003", "value": "11.51", "spread": "3.781"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate bioequivalence (BE) of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted state, linear mixed model analysis was performed on log(Cmax) of saxagliptin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted condition), then 20 subjects provided 97% power to conclude BE with respect to Cmax of saxagliptin. If 5% difference then 20 subjects provided 93% power to conclude BE with respect to Cmax of saxagliptin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% confidence intervals (CIs) for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.011", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.940", "ciUpperLimit": "1.088", "estimateComment": "For Cmax of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: the geometric mean of the Reference formulation in fasted state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log(Cmax) of saxagliptin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed condition), then 20 subjects provided 97% power to conclude BE with respect to Cmax of saxagliptin. If 5% difference then 20 subjects provided 93% power to conclude BE with respect to Cmax of saxagliptin.", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs Reference", "paramValue": "0.999", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.929", "ciUpperLimit": "1.075", "estimateComment": "For Cmax of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Saxagliptin Mean Area Under the Plasma Concentration Time Curve From Time Zero To Time of Last Quantifiable Concentration (AUC [0-T]}", "description": "AUC (0-T) for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48.57", "spread": "12.864"}, {"groupId": "OG001", "value": "49.69", "spread": "12.330"}, {"groupId": "OG002", "value": "54.59", "spread": "12.407"}, {"groupId": "OG003", "value": "55.83", "spread": "12.735"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted and fed states, linear mixed model analysis was performed on log\\[AUC(0-T)\\] of saxagliptin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted condition), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin. If 5% difference then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.029", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.993", "ciUpperLimit": "1.066", "estimateComment": "For AUC(0-T) of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: geometric mean of the Reference formulation in fasted state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log\\[AUC(0-T)\\] of saxagliptin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed condition), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin. If 5% difference then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Means Ratio", "paramValue": "1.021", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.986", "ciUpperLimit": "1.058", "estimateComment": "For AUC(0-T) of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Saxagliptin Mean Area Under the Plasma Concentration Time Curve From Time Zero To Infinity (AUC [0-INF])", "description": "AUC (0-T) for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg), or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.66", "spread": "13.322"}, {"groupId": "OG001", "value": "51.74", "spread": "12.736"}, {"groupId": "OG002", "value": "56.56", "spread": "12.778"}, {"groupId": "OG003", "value": "57.86", "spread": "13.222"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted state, linear mixed model analysis was performed on log\\[AUC(INF)\\] of saxagliptin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted condition), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin. If 5% difference then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.027", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.990", "ciUpperLimit": "1.066", "estimateComment": "For AUC(INF) of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: geometric mean of the Reference formulation in fasted state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log\\[AUC(INF)\\] of saxagliptin and metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of saxagliptin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed condition), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin. If 5% difference then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of saxagliptin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Means Ratio Test vs. Reference", "paramValue": "1.022", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.985", "ciUpperLimit": "1.060", "estimateComment": "For AUC(INF) of saxagliptin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Saxagliptin Mean Plasma Half-life (T-half) and Mean Time of Maximum Observed Plasma Concentration (T-max)", "description": "T-half and T-max for single-dose saxagliptin (2.5 mg), either coadministered with metformin IR (500 mg) or administered as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"title": "T-half", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.86", "spread": "1.367"}, {"groupId": "OG001", "value": "5.55", "spread": "1.135"}, {"groupId": "OG002", "value": "5.75", "spread": "1.119"}, {"groupId": "OG003", "value": "5.72", "spread": "1.146"}]}]}, {"title": "T-max", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.78", "spread": "1.210"}, {"groupId": "OG001", "value": "1.23", "spread": "0.829"}, {"groupId": "OG002", "value": "1.37", "spread": "0.842"}, {"groupId": "OG003", "value": "1.42", "spread": "0.862"}]}]}]}, {"type": "PRIMARY", "title": "Metformin Mean Cmax", "description": "Cmax of single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1030.22", "spread": "293.970"}, {"groupId": "OG001", "value": "1042.52", "spread": "314.365"}, {"groupId": "OG002", "value": "993.32", "spread": "198.653"}, {"groupId": "OG003", "value": "1027.70", "spread": "208.974"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted state, linear mixed model analysis was performed on log(Cmax) of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted and fed), then 20 subjects provided 98% power to conclude BE with respect to Cmax of metformin. If 5% difference then 20 subjects provided 93% power to conclude BE with respect to Cmax of metformin, respectively.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.009", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.939", "ciUpperLimit": "1.084", "estimateComment": "For Cmax of metformin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: geometric mean of the Reference formulation in fasted fed state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log(Cmax) of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed), then 20 subjects provided 98% power to conclude BE with respect to Cmax of metformin. If 5% difference then 20 subjects provided 93% power to conclude BE with respect to Cmax of metformin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.034", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.962", "ciUpperLimit": "1.111", "estimateComment": "For Cmax of metformin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Metformin Mean AUC (0-T)", "description": "AUC (0-T for single-dose metformin (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7403.01", "spread": "1822.749"}, {"groupId": "OG001", "value": "7575.23", "spread": "1832.807"}, {"groupId": "OG002", "value": "7176.78", "spread": "1216.854"}, {"groupId": "OG003", "value": "7502.46", "spread": "1402.256"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted state, linear mixed model analysis was performed on log\\[AUC(0-T)\\] of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of metformin. If 5% difference then 20 subjects provided 95% power to conclude BE with respect to AUC(INF) of metformin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.024", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.964", "ciUpperLimit": "1.088", "estimateComment": "For AUC(0-T) of metformin the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: geometric mean of the Reference formulation in fasted state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log\\[AUC(0-T)\\] of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of metformin. If 5% difference then 20 subjects provided 95% power to conclude BE with respect to AUC(INF) of metformin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.042", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.981", "ciUpperLimit": "1.108", "estimateComment": "For AUC(0-T) of metformin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Metformin Mean AUC(0-INF)", "description": "AUC (0-INF) for single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg) or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7494.67", "spread": "1792.921"}, {"groupId": "OG001", "value": "7689.57", "spread": "1761.119"}, {"groupId": "OG002", "value": "7246.89", "spread": "1215.675"}, {"groupId": "OG003", "value": "7574.17", "spread": "1397.335"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fasted state, linear mixed model analysis was performed on log\\[AUC(INF)\\] of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fasted ), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of metformin. If 5% difference then 20 subjects provided 95% power to conclude BE with respect to AUC(INF) of metformin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.029", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.973", "ciUpperLimit": "1.088", "estimateComment": "For AUC(INF) of metformin, the point estimate and 90% CI were calculated for the ratio of the geometric mean of the Test formulation in fasted state: the geometric mean of the Reference formulation in fasted state"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate BE of FDC tablets (Test) versus co-administration of saxagliptin and metformin IR tablets (Reference) formulations in fed state, linear mixed model analysis was performed on log\\[AUC(INF)\\] of metformin. Factors in the model were sequence, period and treatment as fixed effects, and participant within sequence as a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If no difference between bioavailabilities of metformin from FDC tablet vs. co-administration of saxagliptin tablet and metformin (fed), then 20 subjects provided 99% power to conclude BE with respect to AUC(INF) of metformin. If 5% difference then 20 subjects provided 95% power to conclude BE with respect to AUC(INF) of metformin.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Bioequivalence=90% CIs for the test", "paramType": "Geometric Mean Ratio, Test vs. Reference", "paramValue": "1.042", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.986", "ciUpperLimit": "1.102", "estimateComment": "For AUC(INF) of metformin, the point estimate and 90% confidence interval (CI) were calculated for the ratio of the geometric mean of the Test formulation in fed state: the geometric mean of the Reference formulation in fed state"}]}, {"type": "PRIMARY", "title": "Metformin T-half and T-max", "description": "T-half and T-max for single-dose metformin IR (500 mg), either coadministered with saxagliptin (2.5 mg), or administerd as FDC 2.5 mg saxagliptin/500 mg metformin IR, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"title": "T-Half", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.87", "spread": "5.561"}, {"groupId": "OG001", "value": "12.03", "spread": "9.014"}, {"groupId": "OG002", "value": "8.62", "spread": "3.069"}, {"groupId": "OG003", "value": "8.61", "spread": "3.288"}]}]}, {"title": "T-max", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.18", "spread": "0.919"}, {"groupId": "OG001", "value": "3.08", "spread": "0.762"}, {"groupId": "OG002", "value": "3.96", "spread": "0.204"}, {"groupId": "OG003", "value": "3.87", "spread": "0.680"}]}]}]}, {"type": "SECONDARY", "title": "BMS-510849 Mean Cmax", "description": "Cmax of the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administered as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.32", "spread": "5.094"}, {"groupId": "OG001", "value": "16.10", "spread": "4.967"}, {"groupId": "OG002", "value": "18.40", "spread": "4.140"}, {"groupId": "OG003", "value": "18.72", "spread": "4.280"}]}]}]}, {"type": "SECONDARY", "title": "BMS-510849 Mean AUC (0-T)", "description": "AUC (0-T) for the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administration as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "112.35", "spread": "20.053"}, {"groupId": "OG001", "value": "113.87", "spread": "24.141"}, {"groupId": "OG002", "value": "120.31", "spread": "22.719"}, {"groupId": "OG003", "value": "123.05", "spread": "24.821"}]}]}]}, {"type": "SECONDARY", "title": "BMS-510849 Mean AUC (0-INF)", "description": "AUC (0-T)= for the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administered as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "120.72", "spread": "19.826"}, {"groupId": "OG001", "value": "122.74", "spread": "24.805"}, {"groupId": "OG002", "value": "129.02", "spread": "22.988"}, {"groupId": "OG003", "value": "131.88", "spread": "25.908"}]}]}]}, {"type": "SECONDARY", "title": "BMS-510849 Mean T-half and T-max", "description": "T-half and Tmax of the saxagliptin metabolite BMS-510849, following single-dose saxagliptin (2.5 mg) coadministered with metformin IR (500 mg) or administerd as an FDC 2.5 mg saxagliptin/500 mg metformin IR tablet, under fasted and fed conditions.", "populationDescription": "PK data set, all participants who received study drug", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Day 1: 0 hr, 0.25 hr, 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr, Day 2: 0 hr, 12 hr, Day 3: 0 hr", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"title": "T-Half", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.53", "spread": "1.346"}, {"groupId": "OG001", "value": "6.93", "spread": "1.284"}, {"groupId": "OG002", "value": "6.73", "spread": "1.380"}, {"groupId": "OG003", "value": "6.62", "spread": "1.238"}]}]}, {"title": "T-max", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.40", "spread": "0.965"}, {"groupId": "OG001", "value": "2.30", "spread": "0.965"}, {"groupId": "OG002", "value": "2.35", "spread": "0.774"}, {"groupId": "OG003", "value": "2.53", "spread": "0.727"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With at Least 1 Adverse Event (AE), Death, Serious AE (SAE), or AEs Leading to Discontinuation", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.", "populationDescription": "All Treated Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Day 1 through Day 45, including up to 56 days after last dose of study medication", "groups": [{"id": "OG000", "title": "Co-administration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin (Fasted)", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Co-administration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin (Fed)", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}, {"id": "OG004", "title": "All Treated Participants", "description": "Participants were randomized to received 1 of 4 treatments 1)oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions, 2) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions, 3) oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions, or 4) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions. Participants received all 4 treatments in 1 of 4 sequences: 1-4-2-3, 2-1-3-4, 3-2-4-1, or 4-3-1-2, with a washout period between treatments of at least 1 week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "24"}]}], "classes": [{"title": "Participants with at least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "7"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "AE leading to discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Laboratory Marked Abnormalities", "description": "High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Leukocytes: \\<0.9 x LLN/ \\>1.2 x ULN; blood urea nitrogen (BUN): \\>1.1 x ULN; creatinine: \\>1.33 x BL; phosphorous (P): \\<0.75 x LLN/ \\>1.2 5 x ULN; creatinine kinase (CK): \\>1.5 x ULN; urine blood=use \u22652 x BL if value \u22652+ or BL1+", "populationDescription": "All Treated Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Day 1 through Day 45, including up to 56 days after last dose of study medication", "groups": [{"id": "OG000", "title": "Co-administration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin (Fasted)", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Co-administration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin (Fed)", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}, {"id": "OG004", "title": "All Treated Participants", "description": "Participants were randomized to received 1 of 4 treatments 1)oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions, 2) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions, 3) oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions, or 4) a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions. Participants received all 4 treatments in 1 of 4 sequences: 1-4-2-3, 2-1-3-4, 3-2-4-1, or 4-3-1-2, with a washout period between treatments of at least 1 week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "24"}]}], "classes": [{"title": "High leukocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "High BUN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "High creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Low phosphorus", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "High CK", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "High urine blood", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities", "description": "PR interval, QRS complex, width of QRS, QT interval, and QT corrected for heart rate adjusting for heart rate using either Bazett formula or Fridericia formula were measured. ECG abnormalities were judged to be of medical importance by the Investigator.", "populationDescription": "All Treated Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Period 1 Day 1, Period 2 Day 1, Period 3 Day 1, Period 4 Day 1, Period 4 Day 3", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Relevant Vital Sign Abnormalities", "description": "Mean systolic and diastolic blood pressure, heart rate, respiration, and temperature were assessed.Vital sign abnormalities abnormalities were judged to be of medical importance by the Investigator.", "populationDescription": "All Treated Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Period 1 Day 1, Period 2 Day 1, Period 3 Day 1, Period 4 Day 1, Period 4 Day 3", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participant With Clinically Relevant Physical Examination Abnormalities", "description": "A physical examination was conducted which included height and weight measurements, from which the Body Mass Index was determined. Physical examination abnormalities were judged to be of medical importance by the Investigator.", "populationDescription": "All Treated Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Screen, Period 1 Day -1, prior to discharge", "groups": [{"id": "OG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions"}, {"id": "OG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed-dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions"}, {"id": "OG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions"}, {"id": "OG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "4", "eventGroups": [{"id": "EG000", "title": "Coadministration of Saxagliptin and Metformin IR (Fasted)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 6, "otherNumAtRisk": 24}, {"id": "EG001", "title": "Saxagliptin/Metformin FDC (Fasted)", "description": "Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 3, "otherNumAtRisk": 24}, {"id": "EG002", "title": "Coadministration of Saxagliptin and Metformin IR (Fed)", "description": "Participants received oral coadministration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin IR under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 4, "otherNumAtRisk": 24}, {"id": "EG003", "title": "Saxagliptin/Metformin FDC (Fed)", "description": "Participants received a single oral dose of an FDC tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 1, "otherNumAtRisk": 24}], "otherEvents": [{"term": "PALPITATIONS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 24}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "GASTROINTESTINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "EAR PAIN", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 24}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "LYMPH NODE PAIN", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "RASH", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "RHINORRHOEA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "NASAL CONGESTION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "OROPHARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 24}]}, {"term": "INCREASED UPPER AIRWAY SECRETION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}, {"term": "FATIGUE", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 24}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}